Tumor Obliteration by Resonant Amplification (TOR) A Nonthermal, Spectrally-Targeted Approach to Cancer Disintegration

TL;DR

Tumor Obliteration by Resonant Amplification (TOR) presents a nonthermal, spectrally targeted approach to cancer ablation that relies on phase-locked, resonant actuation to extinguish malignant tissue while preserving healthy structures. By modeling tissue as a small-strain viscoelastic system and enforcing strict safety gates, TOR achieves per-focus extinction within $2.5$–$3.1$ s at energy densities around $0.8$–$1.0$ J/cm$^{3}$, with peak temperature rise $\Delta T_{max}$ below $0.2^{\circ}$C and minimal CEM$_{43}$ exposure. The method demonstrates high spectral fidelity (MMI ~ $0.92$), strong selectivity (SSR ~ $14.6$ circ./$11.2$ infiltrative), and robust margins (ATI $\le 0.8$ of matrix failure), across multiple organ models in simulation. The study further argues for a practical clinical path via robotic integration, real-time spectral monitoring, and a measure-collapse-remeasure loop, offering a margin-assured, dynamic treatment that avoids thermal and cavitation risks while enabling rapid, multifocal ablation. If validated in bench and early trials, TOR could transform tumor management by delivering rapid, targeted, and safe ablations across histologies with minimal collateral impact.

Abstract

Tumor Obliteration by Resonant Amplification (TOR) was evaluated purely in simulation. Forward models in COMSOL, ANSYS, and ABAQUS used the same small-strain rheology, nonthermal/noncavitational limits, and an emulated closed loop (phase-locked actuation plus contrast/safety gating). Over >= 200 Monte Carlo runs per setup, TOR produced per-focus extinction in 2.6-3.2 s at approx. 0.85-0.90 J/cm^3, with selectivity Q = 39 +/- 5, peak temperature rise dT_max <= 0.2 deg C, and CEM43 << 1, consistent with strictly nonthermal operation. Primary indices indicated high spectral fidelity and intrinsic safety margin: MMI = 0.92 +/- 0.03, SSR = 14.6 +/- 3.1 (circumscribed) / 11.2 +/- 2.4 (infiltrative), and ATI <= 0.8 of the matrix-failure threshold. Simulated foci matched FE predictions within +/- 150 um. A unitless reality-adherence score comparing four observables to consolidated literature ranges yielded A = 95% +/- 2% (BCa 95%). Organ-specific estimates were 95.1% (pancreatic ductal adenocarcinoma), 96.0% (prostatic acinar adenocarcinoma), and 94.2% (invasive ductal carcinoma of the breast). The delivery stack - tungsten micro-needle (300-500 um) with 5-25 um tip excursions, phase lock, and amplitude gating - operated in a small-strain, noncavitational regime, keeping off-target strain below safety limits by design. Mechanistically, mode-selective collapse implies suppression of core vesicle biogenesis and nociceptor drive; rim scanning is constrained by healthy-referenced bounds, motivating compact neuroimmune readouts in future tests. Overall, the calibrated multiphysics results support a reproducible, spectrum-locked path from modeling to benchtop: deterministic extinction at low energy, high selectivity, and strict thermal neutrality, with pre-registered experiments planned to confirm the predicted safety and efficacy envelopes.

Figures (11)

• Figure 1: Healthy-referenced targeting and neuroimmune loop neutralization in UST. Conceptual schematic comparing tumor and healthy spectra, rim-focused ring-scan of the malignant core, and neutralization of the tumor-derived sEV–nociceptor loop.
• Figure 2: Mode-selective energy deposition in UST. Finite-element strain–energy density in an infiltrative model showing confinement to malignant core and finger-like projections. The healthy-referenced annulus acts as a dynamic safety boundary, enabling the measure–collapse–remeasure loop.
• Figure 3: Spectral confinement of tumor ablation in UST. Finite-element mesh showing the gradient from tumor core (red) through peritumoral region (green) to healthy tissue (blue); colors denote mode-specific displacement at $\omega^\star$.
• Figure 4: Neuroimmune loop neutralization via spectral extinction. (Left) Tumor sEVs engage nociceptors, driving an immunosuppressive loop. (Center) UST targets tumor spectral modes, enforcing core extinction while keeping delivery below healthy limits. (Right) Fractionated retuning with brief ring-scans prunes rim activity.
• Figure 5: Tripartite vibrational fingerprint. (Left) Healthy interferogram. (Center) Tumor spectrum with additional peaks. (Right) Therapy-relevant spectrum after subtracting healthy modes, leaving tumor-exclusive resonances.